BioSpace News Archive

Company proprietary TAPP and MPAR overdose technology to aid a most vulnerable patient population.

Aldeyra Therapeutics, Inc. announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American Academy of Ophthalmology 2019 Annual Meeting, which takes place October 12-15, 2019 at the Moscone Center in San Francisco, California.

Currax Pharmaceuticals LLC announced a deal whereby Currax obtained patent rights to ONZETRA® Xsail® in North America from OptiNose AS, a subsidiary of OptiNose, Inc..

Pharmaceutical Brands Face Disruptions From Private Label Brands With Over-the-Counter Products Including Amazon’s Basic Care Products

Tangible® Science, an innovator creating a dramatically better contact lens experience for patients and eye care practices, announced the launch of Unity® BioSync™ Contact Lenses.

Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced that the United States Food and Drug Administration has expanded the use of Dysport® for injection to include the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy.

Medtec China 2019, organized by Informa Markets, was inaugurated on September 25 in Shanghai.

IsoPlexis illustrates progress in CAR-T development & bioprocessing with funding, recent data sets, and co-marketing technology note with Miltenyi Biotec, Inc.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for BMN 307, an investigational AAV5-phenylalanine hydroxylase

Beam is a biotechnology company developing precision genetic medicines through base editing